Pondimin & Redux Suite Ruled Not Class-Action

JACKSON, Miss. - The Mississippi Supreme Court has ordered separate trials for seven people who sued obesity drug maker Wyeth-Ayerst Laboratories in Jones County Circuit Court.

A year ago, the Supreme Court ordered separate trials for multiple defendants in lawsuits not only against drug manufacturers but also asbestos lawsuits.

In the Jones County case, the seven joined in claims against Wyeth-Ayerst Laboratories and their prescribing physicians. The plaintiffs generally claimed injuries resulting from taking the Pondimin and Redux, which are prescription drugs manufactured and sold to treat obesity.

Plaintiffs complained that, as a consequence of taking the drugs, they had heart disease and other injuries.
The trial judge refused to order separate trials in the case.

Fenfluramine (Pondimin) contains dexfenfluramine and levofenfluramine. Levofenfluramine may have some activities not directly related to appetite suppression. Dexfenfluramine (Redux) contains only dexfenfluramine. Fen-Phen.

January 31, 2005 in Fen-Phen | Permalink | Comments (0)

3 win $2.5M in diet drug Fen-Phen lawsuit

Thursday, January 6, 2005
ASSOCIATED PRESS

MADISON - Wyeth Pharmaceuticals said a jury has ruled in favor of three women who claimed Wyeth's Pondimin diet drug damaged their heart valves.

The Madison-based drug maker late Tuesday said a Philadelphia jury determined that Wyeth is liable for the $2.5 million in compensatory damages previously determined in the first phase of the trial.

Wyeth will pursue post-trial motions and, if necessary, appeal the verdicts.

The verdicts came at the end of the second phase of the trial that began on Dec. 27. Phase one was completed on Dec. 22.

Pondimin, the fenfluramine half of diet drug combo fen-phen, was pulled from the market in 1997 amid evidence it caused heart-valve damage.

At the close of October, 63,000 suits had been filed against Wyeth over the diet pill, the company said.

January 15, 2005 in Fen-Phen | Permalink | Comments (0)

Pondimin (Fen-Phen) Lawsuit Won

3 win $2.5M in diet drug lawsuit

MADISON - Wyeth Pharmaceuticals said a jury has ruled in favor of three women who claimed Wyeth's Pondimin diet drug damaged their heart valves.

The Madison-based drug maker late Tuesday said a Philadelphia jury determined that Wyeth is liable for the $2.5 million in compensatory damages previously determined in the first phase of the trial.

Lorraine Gordon was awarded $750,000, Sonia Jones $500,000 and Susan Rives $1.25 million.

Wyeth will pursue post-trial motions and, if necessary, appeal the verdicts.

The verdicts came at the end of the second phase of the trial that began on Dec. 27. Phase one was completed on Dec. 22.

Pondimin, the fenfluramine half of diet drug combo fen-phen, was pulled from the market in 1997 amid evidence it caused heart-valve damage.

At the close of October, 63,000 suits had been filed against Wyeth over the diet pill, the company said.

January 6, 2005 in Fen-Phen | Permalink | Comments (0)